Table 1 Characteristics at diagnosis of patients with NHL.
From: Expression of L-type amino acid transporter 1 is a poor prognostic factor for Non-Hodgkin’s lymphoma
Patients (diagnosed in 2006–2018) n = 138 | DLBCL n = 30 | FL n = 69 | |
|---|---|---|---|
Age (years) | 28–91 | 36–90 | 31–91 |
Mean range | 63.2 ± 13.7 | 64.8 ± 14.9 | 62.7 ± 13.1 |
Sex | |||
Male | 72 (52.2%) | 15 (50%) | 31 (44.9%) |
Female | 66 (47.8%) | 15 (50%) | 38 (55.1%) |
Cancer stage | |||
I | 19 (13.8%) | 4 (13.3%) | 7 (10.1%) |
II | 27 (19.6%) | 5 (16.7%) | 15 (21.8%) |
III | 42 (30.4%) | 7 (23.3%) | 25 (36.2%) |
IV | 50 (36.2%) | 14 (46.7%) | 22 (31.9%) |
Serum LDH | |||
Normal | 78 (56.5%) | 8 (26.7%) | 52 (75.4%) |
Elevated | 60 (43.5%) | 22 (73.3%) | 17 (24.6%) |
Hemoglobin | |||
Normal | 103 (74.6%) | 18 (60%) | 56 (81.2%) |
Decreased | 35 (25.4%) | 12 (40%) | 13 (18.8%) |
IPI risk group | |||
Low risk | 6 (8.7%) | 4 (13.3%) | |
Low-intermediate risk | 20 (29%) | 2 (6.7%) | |
High-intermediate risk | 25 (36.2%) | 11 (36.7%) | |
High risk | 18 (26.1%) | 13 (43.3%) | |
FLIPI2 risk category | |||
Low risk | 16 (23.2%) | ||
Intermediate risk | 39 (56.2%) | ||
High risk | 14 (20.3%) | ||
Bone marrow involvement | |||
Yes | 29 (21%) | 5 (16.7%) | 12 (17.4%) |
No | 84 (60.9%) | 19 (63.3%) | 45 (65.2%) |
Not done | 25 (18.1%) | 6 (20%) | 12 (17.4%) |
Extranodal involvement | |||
Yes | 56 (40.6%) | 15 (50%) | 24 (34.8%) |
No | 82 (59.4%) | 15 (50%) | 45 (65.2%) |
Cytogenetic abnormality | |||
Yes | 63 (45.7%) | 12 (40%) | 44 (63.8%) |
No | 61 (44.2%) | 17 (56.7%) | 22 (31.9%) |
Not done | 14 (10.1%) | 1 (3.3%) | 3 (4.3%) |
LAT1 expression | |||
Low | 53 (38.4%) | 1 (3.3%) | 36 (52.2%) |
High | 85 (61.6%) | 29 (96.7%) | 33 (47.8%) |
Ki-67 expression | |||
< 70% | 120 (87%) | 21 (70%) | 68 (98.6%) |
> 70% | 18 (13%) | 9 (30%) | 1 (1.4%) |
